Verve Therapeutics’ loss of Vertex as a partner has generated headlines this week but the gene-editing company’s real make-or-break moment could be just around the corner.
The in vivo base editing biotech announced on 28 February that Vertex was withdrawing from a collaboration established in 2022, which had brought in $25m upfront in cash and had held the promise of up to $406m in development and commercial milestones
Key Takeaways
- Verve has lost two-thirds of its market cap since April 2024, reflecting safety concerns about its former candidate, plus a wider downturn in the once-hyped gene-editing field
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?